SS Innovations International Inc. (NASDAQ: SSII) has supported the launch of Sri Lanka's first robotic cardiac surgery program at Kings Hospital Colombo, marking a significant step in the company's global expansion and the adoption of robotic-assisted cardiac procedures. The program commenced with a robotic-assisted left internal mammary artery (LIMA) takedown performed by Dr. Sudhir Srivastava, founder and chairman of SS Innovations, alongside Kings Hospital cardiothoracic surgeon Dr. Rajitha DeSilva. This development was highlighted in a recent company video describing the program's early activity.
The launch matters because it demonstrates the SSi Mantra 3.0 system's capability in complex cardiac procedures and opens a new market for SS Innovations. Kings Hospital has already completed more than 25 robotic procedures in just three weeks, according to the video, indicating rapid adoption and proficiency. This early success suggests that the technology is well-received and could lead to broader adoption of robotic cardiac surgery in Sri Lanka and the surrounding region.
SS Innovations reported 224 cumulative SSi Mantra installations across 12 countries at the end of the second quarter, underscoring its growing international footprint. The company's second-quarter revenue reached $13.9 million, while robotic procedures increased 143% year over year to 2,528, pointing to rising utilization of the company's installed base. These metrics highlight not only increasing sales but also growing usage per system, which is critical for long-term revenue growth and customer retention.
The next major corporate milestone is regulatory expansion, with SS Innovations pursuing U.S. FDA clearance and European CE marking for the SSi Mantra system. Achieving these certifications would allow the company to enter two of the largest and most lucrative medical device markets, potentially accelerating revenue growth and solidifying its position in the global surgical robotics industry. The successful deployment in Sri Lanka serves as a proof point of the system's versatility and effectiveness, which could support regulatory submissions and commercial efforts in other regions.
For investors, the news is important because it signals execution on the company's international strategy and the potential for continued procedure growth. The latest news and updates relating to SSII are available in the company's newsroom at https://ibn.fm/SSII. As robotic surgery becomes more prevalent, SS Innovations is positioning itself as a key player, and this launch could be a catalyst for further market penetration and partnerships. The company's focus on innovation and expansion bodes well for its competitive standing in the evolving healthcare technology landscape.
